Industry Recognition for Our Hep C Program
Mar 3, 2016
With the Hepatitis Cure Value Program®, Express Scripts combined its scale, focus and innovation to generate more value for clients and to achieve better care for patients.
Express Scripts’ Hepatitis Cure Value Program® solved the unprecedented challenge of providing hepatitis C treatment to all who need it and saving clients tens of thousands of dollars per patient, on average, compared to the previous cost of curative hepatitis C therapies.
We’re proud of the industry-wide ripple effect of our action and the $4 billion saved for the U.S. healthcare system in 2015. In recognition of our action, Express Scripts was recently awarded PBMI’s Excellence Award in the Cost Containment Category.
For the first time, Express Scripts’ drug-specific cost containment management strategies looked beyond changes in formulary status to provide an innovative way to expand access to care while lowering costs. In doing so, Express Scripts combined its scale, focus and innovation to generate more value for clients and to achieve better care for patients.
As a result, the United States cured more patients of hepatitis C in 2015 than in any previous year.
The Cost of a Curative Treatment
Hepatitis C is a slowly developing condition that is the leading cause of chronic liver disease, cirrhosis (scarring of the liver), liver cancer and liver transplantation. About 2.4 million Americans – approximately 75% of those with hepatitis C – have a form of the virus known as genotype 1, which can be cured by Sovaldi® (sofosbuvir), Harvoni® (ledipasvir and sofosbuvir) or Viekira Pak™ (ombitasvir/paritaprevir/ritonavir; dasabuvir). Until Express Scripts introduced the Hepatitis Cure Value Program, the cost of these medications forced many clients to restrict treatment to patients with advanced fibrosis, advanced cirrhosis or other severe manifestations of the disease.
comments powered by